Literature DB >> 23696936

Does progesterone-induced endometrial withdrawal bleed before ovulation induction have negative effects on IUI outcomes in patients with polycystic ovary syndrome?

Xiyuan Dong1, Yu Zheng, Xiuhua Liao, Ting Xiong, Hanwang Zhang.   

Abstract

Polycystic ovary syndrome is a common heterogeneous endocrine disorder in reproductive-age women, with prevalence around 4-12%. The present study was performed to investigate whether progesterone-induced endometrial bleed before ovulation induction affects pregnancy in patients with PCOS who underwent intrauterine insemination (IUI) treatment. A total of 241 IUI cycles were retrospectively analyzed. Patients enrolled in this study underwent ovulation induction with IUI treatment from Jan. 2011 to Dec. 2012. The study group consisted of 184 cycles with progesterone-withdrawal bleed before ovulation induction. The control group included 57 cycles with spontaneous menses. The clinical characteristics, ovulation induction parameters and IUI outcomes, such as pregnancy rate and live birth/ongoing pregnancy rate, were compared between the two groups. We found that patients in induced shedding group had thinner peak endometrium in ovulation induction cycles. Additionally, the ratio of peak endometrial-thickness to baseline endometrial-thickness was lower in induced menses patients. However, the pregnancy rate and live birth/ongoing pregnancy rate per cycle were similar with the control group. Excluding the peak E(2) level, peak E(2)/number of follicles > 15 mm and peak endometrial-thickness/baseline endometrial-thickness, no differences were found in ovulation induction or IUI results between patients used Letrozole or Clomiphene Citrate. In patients undergoing administration with Letrozole, those taking progesterone had thinner endometrium and lower peak endometrial-thickness/baseline endometrial-thickness. However, the pregnancy rate and live birth/ongoing pregnancy rate were not statistically different from patients with spontaneous menses. In conclusion, our study showed that progesterone exerted a negative effect on endometrial development, which seemed to be associated with reduced pregnancy results in ovulation induction with IUI cycles.

Entities:  

Keywords:  Polycystic ovary syndrome; endometrial withdrawal bleed; letrozole; live birth/ongoing pregnancy rate; ovulation induction; pregnancy rate

Mesh:

Substances:

Year:  2013        PMID: 23696936      PMCID: PMC3657371     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

1.  Detrimental effect of induced or spontaneous menses before ovulation induction on pregnancy outcome in patients with polycystic ovary syndrome.

Authors:  Robert F Casper
Journal:  Obstet Gynecol       Date:  2012-05       Impact factor: 7.661

2.  The effect of endometrial thickness on in vitro fertilization (IVF)-embryo transfer/intracytoplasmic sperm injection (ICSI) outcome.

Authors:  J E Okohue; S O Onuh; P Ebeigbe; I Shaibu; I Wada; J I Ikimalo; E E Okpere
Journal:  Afr J Reprod Health       Date:  2009-03

3.  Clomiphene citrate versus letrozole: molecular analysis of the endometrium in women with polycystic ovary syndrome.

Authors:  Kedra L Wallace; Venessia Johnson; Victoria Sopelak; Randall Hines
Journal:  Fertil Steril       Date:  2011-10       Impact factor: 7.329

Review 4.  The treatment of infertility in polycystic ovary syndrome: a brief update.

Authors:  Michael F Costello; Marie L Misso; Jennifer Wong; Roger Hart; Luk Rombauts; Angela Melder; Robert J Norman; Helena J Teede
Journal:  Aust N Z J Obstet Gynaecol       Date:  2012-05-28       Impact factor: 2.100

5.  Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome.

Authors:  Michael P Diamond; Michael Kruger; Nanette Santoro; Heping Zhang; Peter Casson; William Schlaff; Christos Coutifaris; Robert Brzyski; Gregory Christman; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Michael P Steinkampf; Gabriella G Gosman; John E Nestler; Sandra Carson; Evan E Myers; Esther Eisenberg; Richard S Legro
Journal:  Obstet Gynecol       Date:  2012-05       Impact factor: 7.661

6.  Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls--implications for regulation of pubertal maturation.

Authors:  Susan K Blank; Christopher R McCartney; Sandhya Chhabra; Kristin D Helm; Christine A Eagleson; R Jeffrey Chang; John C Marshall
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

7.  Letrozole versus clomiphene citrate: which is better for ovulation induction?

Authors:  Robert F Casper
Journal:  Fertil Steril       Date:  2007-06-27       Impact factor: 7.329

8.  Novel clomiphene "stair-step" protocol reduces time to ovulation in women with polycystic ovarian syndrome.

Authors:  Bradley S Hurst; Jennifer M Hickman; Michelle L Matthews; Rebecca S Usadi; Paul B Marshburn
Journal:  Am J Obstet Gynecol       Date:  2008-12-27       Impact factor: 8.661

9.  Effects of letrozole and clomiphene citrate on the expression of HOXA10 and integrin alpha v beta 3 in uterine epithelium of rats.

Authors:  Shi Hua Bao; Shi Le Sheng; Yi Feng Peng; Qi De Lin
Journal:  Fertil Steril       Date:  2008-02-04       Impact factor: 7.329

10.  The relationship between polycystic ovary syndrome, glucose tolerance status and serum preptin level.

Authors:  Zhiqin Bu; Kakei Kuok; Jie Meng; Rui Wang; Bei Xu; Hanwang Zhang
Journal:  Reprod Biol Endocrinol       Date:  2012-02-06       Impact factor: 5.211

View more
  2 in total

Review 1.  Ovulation Induction for the General Gynecologist.

Authors:  Steven R Lindheim; Tanya L Glenn; Megan C Smith; Pascal Gagneux
Journal:  J Obstet Gynaecol India       Date:  2018-05-12

2.  Ovulation rates in a stair-step protocol with Letrozole vs clomiphene citrate in patients with polycystic ovarian syndrome.

Authors:  S Thomas; I Woo; J Ho; T Jones; R Paulson; K Chung; K Bendikson
Journal:  Contracept Reprod Med       Date:  2019-12-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.